
No Stock Yet
No Data
Comments on the semiannual report of Xianjian Technology (01302.HK) in 2021: the performance exceeded expectations and steadily implemented the "internationalization + platform" innovation and R & D strategy.
First Health Technology (01302.HK): rapid volume products of left atrial appendage have been approved one after another.
Comments of Xianjian Technology (01302.HK) Co., Ltd.: semi-annual report results grow rapidly and adhere to the strategy of innovation and international development.
Xianjian Technology (01302.HK): great increase in performance in the first half of the year, strong technological strength and long-term improvement.
Comments on the 2020 Annual report of Xianjian Technology (01302.HK): the performance is in line with the expected pipeline to enter the harvest period.
Xianjian Technology (01302.HK): innovative equipment Dark Horse intervention Pearl of consumables
Guoxin Securities: the DRGs pilot project is further expanded to grasp the three main lines of pharmaceutical investment
Comments on the announcement of Xianjian Technology (01302.HK): the future growth of small and beautiful innovative devices is promising.
First Health Technology (01302.HK): three business segments support performance growth products all over the world
Pioneer Technology (01302.HK): innovation leads the development of products into a comprehensive harvest period
Loading...
No Stock Yet